The fibroblast growth factor receptors (FGFRs) are a family of ligand-activated, membrane-spanning tyrosine kinases. Mutations in several human FGFR genes have been identified as playing a role in certain disorders of bone growth and development. One of these, Crouzon syndrome, an autosomal dominant disorder causing craniosynostosis, has been associated with mutations in the human FGFR-2 gene. We report here that microinjection of Xenopus embryos with RNA encoding an FGFR-2 protein bearing a Cys Tyr mutation (FGFR-2CS) found in Crouzon syndrome results in fibroblast growth factor (FGF)-independent induction of mesoderm in animal pole explants. Wild-type FGFR-2 did not induce mesoderm when injected at similar doses. The effects of the mutant receptor were blocked by co-expression of dominant negative mutants of either Raf or Ras. Analysis of the mutant receptor protein expressed in Xenopus oocytes indicates that it forms covalent homodimers, does not bind radiolabeled FGF, and has increased tyrosine phosphorylation. These results indicate that FGFR-2CS forms an intermolecular disulfide bond resulting in receptor dimerization and ligand-independent activation that may play a role in the etiology of Crouzon syndrome.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				N. E. Hatch, M. Hudson, M. L. Seto, M. L. Cunningham, and M. Bothwell Intracellular Retention, Degradation, and Signaling of Glycosylation-deficient FGFR2 and Craniosynostosis Syndrome-associated FGFR2C278F J. Biol. Chem., September 15, 2006; 281(37): 27292 - 27305. [Abstract] [Full Text] [PDF]

				X. Yang, D. Kovalenko, R. J. Nadeau, L. K. Harkins, J. Mitchell, O. Zubanova, P.-Y. Chen, and R. Friesel Sef Interacts with TAK1 and Mediates JNK Activation and Apoptosis J. Biol. Chem., September 10, 2004; 279(37): 38099 - 38102. [Abstract] [Full Text] [PDF]

				O. A. Ibrahimi, F. Zhang, A. V. Eliseenkova, R. J. Linhardt, and M. Mohammadi Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity Hum. Mol. Genet., January 1, 2004; 13(1): 69 - 78. [Abstract] [Full Text] [PDF]

				D. M. Ornitz and P. J. Marie FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease Genes & Dev., June 15, 2002; 16(12): 1446 - 1465. [Full Text] [PDF]

				A. E. Kearns, M. M. Donohue, B. Sanyal, and M. B. Demay Cloning and Characterization of a Novel Protein Kinase That Impairs Osteoblast Differentiation in Vitro J. Biol. Chem., November 2, 2001; 276(45): 42213 - 42218. [Abstract] [Full Text] [PDF]

				O. A. Ibrahimi, A. V. Eliseenkova, A. N. Plotnikov, K. Yu, D. M. Ornitz, and M. Mohammadi Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome PNAS, May 30, 2001; (2001) 121183798. [Abstract] [Full Text] [PDF]

				J. A. Greenwald, B. J. Mehrara, J. A. Spector, S. M. Warren, P. J. Fagenholz, L. P. Smith, P. J. Bouletreau, F. E. Crisera, H. Ueno, and M. T. Longaker In Vivo Modulation of FGF Biological Activity Alters Cranial Suture Fate Am. J. Pathol., February 1, 2001; 158(2): 441 - 452. [Abstract] [Full Text] [PDF]

				Z. Vajo, C. A. Francomano, and D. J. Wilkin The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans Endocr. Rev., February 1, 2000; 21(1): 23 - 39. [Abstract] [Full Text]

				D. Rice, T Aberg, Y Chan, Z Tang, P. Kettunen, L Pakarinen, R. Maxson, and I Thesleff Integration of FGF and TWIST in calvarial bone and suture development Development, January 5, 2000; 127(9): 1845 - 1855. [Abstract] [PDF]

				H. Kim, D. Rice, P. Kettunen, and I Thesleff FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development Development, January 4, 1998; 125(7): 1241 - 1251. [Abstract] [PDF]

				F. Wang, M. Kan, K. McKeehan, J.-H. Jang, S. Feng, and W. L. McKeehan A Homeo-interaction Sequence in the Ectodomain of the Fibroblast Growth Factor Receptor J. Biol. Chem., September 19, 1997; 272(38): 23887 - 23895. [Abstract] [Full Text] [PDF]

				M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, B. K. Yeh, S. R. Hubbard, and J. Schlessinger Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors Science, May 9, 1997; 276(5314): 955 - 960. [Abstract] [Full Text]

				S Iseki, A. Wilkie, J. Heath, T Ishimaru, K Eto, and G. Morriss-Kay Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2 Development, January 9, 1997; 124(17): 3375 - 3384. [Abstract] [PDF]

				M. Kan, F. Wang, M. Kan, B. To, J. L. Gabriel, and W. L. McKeehan Divalent Cations and Heparin/Heparan Sulfate Cooperate to Control Assembly and Activity of the Fibroblast Growth Factor Receptor Complex J. Biol. Chem., October 18, 1996; 271(42): 26143 - 26148. [Abstract] [Full Text] [PDF]

				K. M. Neilson and R. Friesel Ligand-independent Activation of Fibroblast Growth Factor Receptors by Point Mutations in the Extracellular, Transmembrane, and Kinase Domains J. Biol. Chem., October 4, 1996; 271(40): 25049 - 25057. [Abstract] [Full Text] [PDF]

				O. A. Ibrahimi, A. V. Eliseenkova, A. N. Plotnikov, K. Yu, D. M. Ornitz, and M. Mohammadi Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome PNAS, June 19, 2001; 98(13): 7182 - 7187. [Abstract] [Full Text] [PDF]